PUBLIC COMPANY
saveMIRUM
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.biopharma_dive · 2h ago
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a rollSummit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene t…biospace · 7h ago
- Mirum reports Phase 3 victory for acquired hepatitis D medMirum Pharmaceuticals’ recently purchased chronic hepatitis delta treatment has scored a Phase 3 win, adding momentum behind the company’s pipeline and commercial future. More than half of patients…endpoints · 1d ago
- FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseaseThe approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…biospace · 2d ago
- Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, VirA phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead S…fiercebiotech · 2d ago
- FDA approves Mirum’s drug for ultra-rare soft tissue diseaseThe FDA has approved the third treatment for a debilitating genetic disease that turns muscle and connective tissue to bone. Mirum Pharmaceuticals’ zilurgisertib, which blocks the ALK2 receptor, wi…endpoints · 4d ago
- Chutes & Ladders—Travere chief makes way for former Amicus CEOTravere Therapeutics CEO Eric Dube, Ph.D., is stepping down after overseeing the launch of the rare kidney disease drug Filspari.fiercebiotech · 6d ago
- Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneTakeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.fiercebiotech · 20d ago
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 1mo ago
- Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pillPlus, news about Merck, MultiValent Biotherapies, Alvotech, enGene, Mirum, and Adaptive Biotechnologies. 💸 Eli Lilly acquires another pain biotech: The Indianapolis pharma giant has made its 11th…endpoints · 3mo ago
comments(0)
5-min edit window · permanent after that